Living cells cool much slower than our current understanding of heat conduction can explain, according to new research from the University of Tokyo. Researchers used two techniques — high-speed temperature mapping and artificial heating — to observe how heat dissipated from living cells and similar-sized artificial, fluid-filled sacs (liposomes). While heat dispersed quickly from the artificial liposomes as expected, cells cooled significantly more slowly due to other biomolecules within the cell. Understanding the process behind slower heat dissipation within cells could affect how we treat conditions linked to changes in body temperature, such as epilepsy, inflammation and cancer.

Researchers at the Faculty of Information Technology at the University of Jyväskylä have used artificial intelligence to speed up the analysis of colorectal cancer samples and predict the functioning of the cells’ DNA repair mechanism. The AI model's analysis can help shorten diagnosis times, reduce costs, and improve the analysis's accuracy. The research was conducted in collaboration with the Central Finland Welfare Region and is co-funded by the European Union.

CHICAGO, MAY 27, 2026 ― In honor of their outstanding contributions to oncology, Sharon Giordano, M.D., chair of Breast Medical Oncology, and Eduardo Vilar-Sanchez, M.D., Ph.D., chair ad interim of Clinical Cancer Prevention, from The University of Texas MD Anderson Cancer Center will receive Special Awards at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. 

For the first time, researchers have shown that a new metabolic process is altered in cancer cells that makes them resistant to DNA-damaging agents.

Researchers from the University of Notre Dame have published the first known detailed study of breast cancer tissue from Native American women. The study, published in npj Precision Oncology, reveals important molecular differences that may impact the efficacy of therapies for female, Native American breast cancer patients.

A study by IRB Barcelona and Centro de Investigación del Cáncer in Salamanca demonstrates that eliminating mutated KRAS protein using PROTACs induces rapid tumour regression in mouse models of lung adenocarcinoma.

The work identifies resistance mechanisms distinct from those observed with classic KRAS inhibitors, a relevant finding as the first KRAS degraders are already in clinical trials.

Published in Cancer Research, the developed model could help evaluate future targeted protein degradation-based therapies against other oncoproteins.